Mattress Firm (MFRM) - FREE Research Report

Fendrich Stephen G. who is Chief Strategy Officer at Mattress Firm sold 500 shares at $30.00 on Nov. 5, 2013. Following this transaction, the Chief Strategy Officer owned 230,235 shares meaning that the stake was reduced by 0.22% with the 500 share transaction.

The shares most recently traded at $32.09, up $2.09, or 6.51% since the insider transaction. Historical insider transactions for Mattress Firm go as follows:

  • 4-Week # shares sold: 833
  • 12-Week # shares sold: 8,588
  • 24-Week # shares sold: 1.3 million

The average volume for Mattress Firm has been 259,300 shares per day over the past 30 days. Mattress Firm has a market cap of $1.1 billion and is part of the consumer goods sector and consumer durables industry. Shares are up 28.58% year to date as of the close of trading on Tuesday.

Mattress Firm Holding Corp., through its subsidiaries, operates as a specialty retailer of mattresses, and related products and accessories in the United States. The company has a P/E ratio of 23.2. Currently there are 6 analysts that rate Mattress Firm a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MFRM - FREE

TheStreet Quant Ratings rates Mattress Firm as a hold. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and robust revenue growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, generally higher debt management risk and disappointing return on equity. Get the full Mattress Firm Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

ICU Medical Wins Big Price Cut to Buy Pfizer's Hospira Unit

These 5 Health Care Stocks Are Breaking Out This Christmas

ICU Medical (ICUI) Stock Closed Higher on $1 Billion Pfizer Deal

Stocks Hold Mixed as Crude Settles Above $50, Wall Street Eyes Jobs Report